Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines. Headquartered in Watertown, Massachusetts, with research operations in Sweden, the company utilizes its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match therapies to patients based on protein signatures rather than genetic mutations. Its lead clinical candidate, ACR-368, is a targeted small molecule inhibitor being evaluated in Phase 2 trials for endometrial, ovarian, and urothelial cancers.
Acrivon is a pre-revenue, clinical-stage biopharmaceutical company. It has no products approved for commercial sale and has not generated product revenue, so it has no commercial customers or customer concentration.